Bevacizumab, a recombinant humanized monoclonal antibody that limits angiogenesis by inhibiting vascular endothelial growth factor (VEGF) and the first molecular-target agent introduced in the gynecological field, has been established as a standard therapy for patients with ovarian cancer based on the prolongation of PFS shown in previous studies. This evidence concerns the gene VEGFA and ovarian cancer.